Nov 3, 9:00 AM ET
PTC Therapeutics' Board of Directors authorized a share repurchase program allowing the company to buy back up to $500 million of its common stock, subject to market conditions. The filing does not give a timing or schedule for purchases, and the company says repurchases will be made at management's discretion and reported in its Form 10-Q and Form 10-K filings.
- Authorization: up to $500 million of outstanding common stock, announced November 3, 2026
- Repurchases may be made from time to time at management's discretion, subject to market conditions
- Methods include open-market transactions with pre-set trading plans, privately negotiated deals, and accelerated share repurchases
- CEO Matthew B. Klein said the program leaves financial flexibility to support existing programs and pursue potential business development transactions
Read the filing on SEC.gov ↗
Oct 29, 4:10 PM ET
PTC Therapeutics reported third-quarter 2026 total revenue of $358 million, up from $211.0 million a year earlier, and raised its full-year 2026 total and product revenue guidance. The company also recorded a net loss of $51.7 million, compared with net income of $15.9 million in the prior-year quarter, after a $111.0 million acquired in-process R&D charge for the ST-920 Fabry gene therapy.
- Q3 2026 total revenue was $357.8 million, versus $211.0 million in Q3 2025; Sephience net product revenue was $181.9 million.
- Net loss was $51.7 million ($0.62 per share) versus net income of $15.9 million a year earlier, including the $111.0 million ST-920 charge.
- Full-year 2026 product revenue guidance was raised to $960 to $990 million from $850 to $950 million; total revenue guidance is $1.29 to $1.32 billion.
- Cash, cash equivalents and marketable securities were $2,127.9 million on September 30, 2026.
Read the filing on SEC.gov ↗
Aug 28, 4:06 PM ET
PTC Therapeutics entered an asset purchase agreement on August 25, 2026 to acquire ST-920, an AAV gene therapy candidate for Fabry disease, from bankrupt Sangamo Therapeutics. The deal carries a $111 million upfront payment plus up to $100 million in contingent milestones tied to FDA approval, and closing requires Bankruptcy Court approval, which is scheduled for a hearing on September 10, 2026.
- Upfront payment of $111 million, plus up to $100 million in contingent milestones ($80 million on accelerated approval and $20 million on full approval)
- Acquisition is subject to Bankruptcy Court approval (hearing scheduled September 10, 2026) and Hart-Scott-Rodino waiting period expiration
- Either party may terminate if closing has not occurred by October 15, 2026, subject to specified exceptions
- Representations and warranties do not survive closing and there is no indemnification for breaches
Read the filing on SEC.gov ↗
Jul 30, 4:05 PM ET
PTC Therapeutics reported second-quarter 2026 total revenue of $360.5 million, up from $178.9 million a year earlier, and net income of $83.5 million, compared with a net loss of $64.8 million in the prior-year quarter. The company raised its 2026 product revenue guidance to $850 million to $950 million and its total revenue guidance to $1.18 billion to $1.28 billion, and it also appointed Hege Sollie-Zetlmayer, its former Chief Human Resources Officer, to the board.
- Q2 2026 total revenue was $360.5 million, including $238.8 million of net product revenue and a $50.0 million Novartis milestone recorded as collaboration revenue.
- Full-year 2026 product revenue guidance was raised to $850 million to $950 million from $750 million to $850 million.
- Sephience generated $151.3 million in Q2 2026 net product revenue; cash, cash equivalents and marketable securities were $2.2 billion as of June 30, 2026.
- Hege Sollie-Zetlmayer was appointed to the board effective July 28, 2026, filling a vacancy.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.